Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study
In routine practice with dosing individualized according to clinical condition, response, and tolerability, osilodrostat was effective and well tolerated regardless of CS etiology and severity.
Authors
- Adriana G. Ioachimescu (ORCID: https://orcid.org/0000-0002-5292-9802)
- Michael S. Broder (ORCID: https://orcid.org/0000-0002-2049-5536)
- Maria Fleseriu (ORCID: https://orcid.org/0000-0001-9284-6289)
- Jamie Ellen Padgett (ORCID: https://orcid.org/0000-0002-7484-2871)
- Joanna L. Spencer-Segal (ORCID: https://orcid.org/0000-0003-0467-2173)
- Kevin C.J. Yuen (ORCID: https://orcid.org/0000-0002-8169-2728)
- Ashis K Das
- Richard Joseph Auchus (ORCID: https://orcid.org/0000-0001-6815-6181)
- Kelley Dacus (ORCID: https://orcid.org/0009-0005-1323-6818)
- Elizabeth Babler
- Cynthia Campos (ORCID: https://orcid.org/0000-0003-2277-0068)
- Wenyu Huang (ORCID: https://orcid.org/0000-0002-7329-1887)
Institutions
- Northwestern University (US)
- Barrow Neurological Institute (US)
- St. Joseph's Hospital and Medical Center (US)
- University of Arizona (US)
- Oregon Health & Science University (US)
- Medical College of Wisconsin (US)
- University of Michigan (US)
- Partnership for Health Analytic Research (US)
- Neurological Surgery (US)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1210/jendso/bvaf046
- Citations
- 12
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 15.54
Funders
- Recordati Rare Diseases
- U.S. Army